Stratifind, Inc.

Website
Molecular Diagnostics

Company Bio

Visit website ↗Explore our full portfolio & program companies
Founders

LvlUp insightsGenerated from LvlUp’s portfolio data and the company’s own updates
Similar companies

More in the LvlUp portfolio

See all →

Building something ambitious?

LvlUp Ventures backs founders from first check to late stage.

Apply for funding
Igor Sokolovsky, Partha Ray
Seed
United States
BioTech, HealthTech
Stratifind commercializes an NGS-based, pan-cancer molecular diagnostic offered as a laboratory-developed test (LDT). We market the test to oncologists, who order it for individual cancer patients. Tumor tissue is sent to a partner CLIA laboratory that performs the wet-lab workflow, while Stratifind runs centralized bioinformatics and generates a patient-specific clinical report with therapy guidance. Revenue is generated through reimbursement from Medicare and commercial payers using existing CPT codes; no FDA approval is required operate and no special approval are required to bill Medicare or commercial payors. The model is asset-light, leveraging outsourced lab operations while retaining ownership of algorithms, interpretation, and reporting. Beyond clinical care, Stratifind plans to generate additional revenue by supporting academic and pharmaceutical partners through translational research and clinical trial services. The platform is designed for expansion beyond the U.S. into international markets with similar pathology frameworks with focus on private pay model.
Prognostic and predictive pan-cancer RNA + DNA testing

Stratifind delivers pan-cancer molecular diagnostics that combine RNA and DNA analysis to inform treatment selection. Its RainDanceEQ test provides both prognostic and predictive insights to guide precision oncology decisions across tumor types. By unifying transcriptomic and genomic signals in a single assay, Stratifind helps clinicians choose evidence-based therapies.